EFEITO DAS ISOFLAVONAS SOBRE A DISCINESIA OROFACIAL E A NEUROINFLAMAÇÃO EM RATOS TRATADOS COM HALOPERIDOL

Schizophrenia is a serious mental illness and its pharmacological treatment consists of the administration of antipsychotics, such as haloperidol. Treatment with haloperidol often causes extrapyramidal motor disorders, such as tardive dyskinesia (TD). DT is a movement disorder characterized by invol...

Descripción completa

Detalles Bibliográficos
Autor: Mezzomo, Natália Fernandes
Tipo de recurso: tesis de maestría
Estado:Versión publicada
Fecha de publicación:2021
País:Brasil
Institución:Universidade Franciscana (UFN)
Repositorio:Biblioteca Digital de Teses e Dissertações da Universidade Franciscana (UFN)
Idioma:portugués
OAI Identifier:oai:tede.universidadefranciscana.edu.br:UFN-BDTD/986
Acceso en línea:http://www.tede.universidadefranciscana.edu.br:8080/handle/UFN-BDTD/986
Access Level:acceso embargado
Palabra clave:Antipsicóticos. Discinesia tardia. Isoflavonas. Neuroinflamação.
Antipsychotics. Tardive dyskinesia. Isoflavones. Neuroinflammation.
Ciências da Saúde e da Vida
Descripción
Sumario:Schizophrenia is a serious mental illness and its pharmacological treatment consists of the administration of antipsychotics, such as haloperidol. Treatment with haloperidol often causes extrapyramidal motor disorders, such as tardive dyskinesia (TD). DT is a movement disorder characterized by involuntary movements involving the mouth, tongue and, sometimes, the limbs and trunk, and can also be studied in animal models, being called orofacial dyskinesia (DO). So far, there is no effective treatment for TD and alternatives have been sought. Thus, the objective was to investigate the effect of isoflavones on DO and haloperidol-induced neuroinflammation in rats, and additionally the effect of treatments on oxidative parameters. For that, male Wistar rats were treated with haloperidol decanoate (1mg / kg / day) and / or isoflavones (80 mg / kg / day) for 28 days. After 24 h of the last administration, the rats were submitted to behavioral evaluation to quantify the movements of chewing in the vacuum (MMV) and also the evaluation of the locomotor activity. Afterwards, the animals were sacrificed and the striatum was dissected and used to measure pro-inflammatory cytokines and the cortex used for the analysis of oxidative parameters. Haloperidol treatment reduced locomotor activity and increased the number of MMV, while co-treatment with isoflavones was able to reverse hypolocomotion and reduce the number of MMV. In addition, haloperidol caused a significant increase in proinflammatory cytokines (interleukin-1β [IL-1β], tumor necrosis factor-α [TNF-α] and interleukin-6 [IL-6] and co-treatment with isoflavones was able to reduce the levels of IL -1β and TNF-α, but not IL-6. For the analyzes in cortex, there was a reduction in the levels of thiols for the group treated with haloperidol and the co-treatment with isoflavones showed no difference. However, when the levels of thiobarbituric acid reactive substances (TBARS) were measured, the haloperidol group showed a significant reduction, which was reversed by treatment with isoflavones In addition, a positive correlation was found between the levels of IL-1β and TNF-α and MMV. It is believed that the beneficial effect found with this treatment is mainly related to the potential anti-inflammatory effect of isoflavones in reducing neuroinflammation, as well as associated with its antioxidant effect.